Skip to main content

Home/ MaRS/ Group items tagged OICR

Rss Feed Group items tagged

Assunta Krehl

Dr. Calvin Stiller appointed Chair of Board of Directors - Ontario Institute for Cancer... - 0 views

  • The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board.
  • He succeeds Dr. John Evans, who was the first Chair and who will continue to serve as a board member.
  • Dr. Stiller co-founded the MaRS Centre in Toronto
  •  
    The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board. Mention of Dr. Stiller Co-Founding MaRS.
  •  
    The Board of Directors of the Ontario Institute for Cancer Research (OICR) has appointed Dr. Calvin Stiller as the Chair of the Board. Mention of Dr. Stiller Co-Founding MaRS. Jan 21, 2009
Assunta Krehl

Diamond Schmitt Architects to design cancer research lab space at MaRS in Toronto - Dai... - 0 views

  •  
    "Diamond Schmitt Architects will design research laboratory space for the Ontario Institute for Cancer Research (OICR) at the MaRS Phase II west tower currently under construction in downtown Toronto." MaRS Phase II occupancy is slatted for 2013.
Assunta Krehl

The New Face of Cancer - The Scientist - June 2, 2010 - 0 views

  •  
    The Ontario Institute for Cancer Research (OICR) is applying the newest concepts in life sciences-stem cell therapies, personalized medicine-to one of the oldest diseases.
Assunta Krehl

Ontario Institute for Cancer Research - The Scientist - June 3, 2010 - 0 views

  •  
    The Ontario Institute for Cancer Research (OICR) is a new center of excellence. It is moving Ontario to the forefront of discovery and innovation in cancer research
Assunta Krehl

From `Eureka!' to real help for cancer patients - The Star - 0 views

  •  
    Tom Hudson is announced as the President and Scientific Director of the Ontario Institute for Cancer Research (OICR).
  •  
    Tom Hudson is announced as the President and Scientific Director of the Ontario Institute for Cancer Research (OICR). Nov 13, 2006
Assunta Krehl

OICR invests $1 million in the further development of two new cancer treatments - Canad... - 0 views

  •  
    Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) announced an investment of $1 million towards the development of two new promising cancer therapies. OncoTek Drug Delivery Inc (a subsidiary of Receptor Therapeutics) is one of the recipients.
Cathy Bogaart

Creative. Competitive. Canada. (Video on Vimeo) - 0 views

  •  
    MaRS and MaRS tenant OICR were two of many locations for a great video promoting businesses and sectors across Canada. It's being shown to international media and visitors during the Olympics. See us at time index 00:54.
Assunta Krehl

DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Bas... - 0 views

  •  
    DLVR Therapeutics Inc. ("DLVR") - a privately-held biotechnology company announced it completed its seed round investment. University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) are investors in the company.
Assunta Krehl

Building a Successful Biotech Incubator - 0 views

  • MaRS aggregates the discovery pipelines of its member institutions, which include three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.
  • MaRS is another good example. Located in the heart of downtown Toronto, the MaRS facility is less than a mile from five major teaching hospitals, the Ontario legislature, and the University of Toronto. More than two dozen research institutes and Toronto’s financial district are also nearby.
  • Consequently, MaRS is a vertical incubator, with a wide variety of companies and stages of development. That mix helps companies better understand the conditions that foster growth. MaRS is home to more than 65 organizations, including The Hospital for Sick Children, the Ontario Institute for Cancer Research, Merck Frosst Canada, the McEwen Centre for Regenerative Medicine, Celtic House Venture Partners, AIM Therapeutics, and AstraZeneca Canada.
  • ...3 more annotations...
  • “Collaboration is the essence of the new economy,” insists Ross Wallace, director of strategic partnerships at MaRS. “There’s a new focus on the power of institutions to generate intellectual property and ideas, and then build around them.”
  • MaRS has a virtual education program dubbed “Entrepreneurship 101.” One February class features budgeting, another agrifood innovation. The classes are available at no cost, and anyone can register. The program also includes blogs and discussion groups such as the drug development and cancer targets groups. So far, MaRS has relied on viral marketing to get the word out.
  • To provide that expertise, MaRS developed the MaRS Venture Group. This team of experienced investors, entrepreneurs, technology experts, and advisors works with companies to help them bridge the gap between entrepreneurial start-up and experienced growth company. The Venture Group provides market intelligence as well  as advisory services such as strategic planning, partnership and alliance building, intellectual property management, marketing and communications, sales strategy, channel development, financing, and human resource development. It works with groups outside the MaRS orbit, too.
  •  
    To have a successful biotech initiative proximity to academic hubs and capital remains a crucial factor in hatching a thriving cluster. MaRS Discovery District is a good example of a vertical incubator and offers many services to help entrepreneurs at different stages.
Assunta Krehl

Ontario Institute for Cancer Research Plans Hires, Increased Commercial Activities - Ge... - 0 views

  •  
    The Ontario Institute for Cancer Research in 2010 will grow its workforce, step up efforts to commercialize discoveries, and aim to fulfill research goals to be detailed in a second strategic plan set to be submitted next month to provincial officials, according to the institute's president and scientific director, Tom Hudson.
Assunta Krehl

Ontario Minister of Research and Innovation - BioscienceWorld - May 6, 2010 - 1 views

  •  
    Hon. John Milloy, Minister of Research and Innovation and Minister of Training, Colleges and Univesities, states "Ontario has big expectations and goals for the life sciences industry and commercialization." MaRS is an innovation centre in Toronto.
Assunta Krehl

MaRS research and innovation hub to expand: Phase two construction will create 4,000 di... - 1 views

  •  
    MaRS Discovery District Phase II construction is now underway and scheduled for completion in September 2013. Public Health Ontario and Ontario Institute for Cancer Research will be the anchor tenants in the Phase II development.
Assunta Krehl

Three red cranes on Hospital Row signal a new future for MaRS construction - National P... - 0 views

  •  
    MaRS Discovery District Phase II construction is now underway and scheduled for completion in September 2013. Public Health Ontario and Ontario Institute for Cancer Research will be the anchor tenants in the Phase II development.
1 - 14 of 14
Showing 20 items per page